Exciting lectures and discussions on therapeutic fusion proteins
Laupheim, Germany, April 11, 2016 / B3C newswire / -- The Laupheim Biotech Days – formerly known as– provide a unique platform for the international exchange of knowledge, ideas and expertise. A comprehensive overview is given and experts discuss cutting-edge technologies and techniques. The 4th Laupheim Biotech Days will take place June 13 to 14, 2016.
The event is organized by Rentschler, a leading contract development and manufacturing organization focused on biopharmaceuticals.
This conference with the title “Fusion Proteins - delivering novel therapeutic options” is focused on the state of the art in developing fusion proteins as biopharmaceuticals, shedding light on the immense potential of design and functionality. Fusion proteins belong to the most lucrative biotech drugs. The highly diverse pipeline is constantly growing with more than 80 molecules in clinical trials and five newly approved molecules in 2014 alone. This dynamic growth is primarily driven by three trends: Establishing platform technologies to extend plasma half-life, innovative approaches addressing multiple targets simultaneously and novel toxic constructs with superior selectivity. Therefore, it is worthwhile to dedicate a closer look to this exciting class of therapeutics.
A highlight of the event are the presentations by international speakers. Topics are among others toxic constructs, antibody derived molecules and bispecific scaffolds. At the first conference day, you will have the opportunity to participate at a tour of Rentschler’s facility. There will be also an industrial exhibition with companies showing their innovations and services. The deadline to register is May 13, 2016. Please register now.
For further information about the conference please visit www.biotech-days.com.
